English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Open

Presents the pdf analysis as premium feature

PDF Analysis

Insights

Presents the summarisation as premium feature

Summarisation

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Conley and Hartmann (1, 2) have reported the existence of a disorder of blood clotting in two patients with systemic lupus erythematosus. In both cases there were severe hemorrhagic symptoms associated with prolongation of the clotting time and the presence of a substance interfering with the interaction of thromboplastin and prothrombin. Previous studies in this laboratory (3) had suggested that the L. E. cell factor required thromboplastin or some component thereof, in order to act on leukocytes. A possible relationship between these two sets of data suggested itself: the L. E. cell factor, reacting in some way with thromboplastin, could inhibit thromboplastin in turn from reacting with prothrombin. If this hypothesis were valid, every blood containing the L. E. cell factor should show impaired thromboplastin function. The clotting disorder described might thus be a characteristic feature of systemic lupus. To test this hypothesis, a systematic survey of blood coagulation in every available patient with systemic lupus erythematosus was undertaken.

A DISORDER OF BLOOD COAGULATION IN SYSTEMIC LUPUS ERYTHEMATOSUS 12